Nanoparticle therapeutics for prostate cancer treatment

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue SUPPL. 1, 2012, Pages

  Sanna, Vanna ^a   Sechi, Mario ^b  

^a Porto Conte Ricerche Srl   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Diagnosis; Nanoparticles; Prostate cancer; Targeted nanoparticles; Theranostic

Indexed keywords

ANTICANCER DRUG; CHEMOTHERAPEUTIC AGENTS; CLINICAL DEVELOPMENT; CONTROLLED RELEASE; HYPERSENSITIVITY REACTION; IMAGING CONTRAST; MALIGNANT LESION; NANO-DEVICES; NANOMEDICINES; PROSTATE CANCERS; TARGETED DELIVERY; TARGETED NANOPARTICLE; THERANOSTIC; VASCULATURE;

DISEASE CONTROL; DISEASES; DRUG PRODUCTS; HEALTH CARE; NANOPARTICLES; NANOTECHNOLOGY; TUMORS;

DIAGNOSIS;

BIND 014; CARBON NANOTUBE; CREMOPHOR; CURCUMIN; DOCETAXEL; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; LIPOSOME; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYLACTIC ACID; POLYMER; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER SCREENING; CHEMOPROPHYLAXIS; CONTROLLED RELEASE FORMULATION; DIET THERAPY; DRUG DELIVERY SYSTEM; HUMAN; MOLECULARLY TARGETED THERAPY; NANODEVICE; NANOEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PROSTATE CANCER; REVIEW; TEA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; NANOMEDICINE; NANOPARTICLES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84865587995     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.05.009     Document Type: Review

References (50)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
2. Wang M.D., Shin D.M., Simons J.W., Nie S. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther 2007, 7:833-837.
3. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
5. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
6. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
7. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
8. Bharali D.J., Mousa S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther 2010, 128:324-335.
9. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharmacol 2008, 5:505-515.
10. Bae K.H., Chung H.J., Park T.G. Nanomaterials for cancer therapy and imaging. Mol Cells 2011, 31:295-302.
11. http://www.cancer.gov/cancertopics/types/prostate.
12. Siddiqui I.A., Mukhtar H. Nanochemoprevention by bioactive food components: a perspective. Pharm Res 2010, 27:1054-1060.
13. Nair H.B., Sung B., Yadav V.R., Kannappan R., Chaturvedi M.M., Aggarwal B.B. Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol 2010, 80:1833-1843.
14. Leonarduzzi G., Testa G., Sottero B., Gamba P., Poli G. Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem 2010, 17:74-95.
15. Yang C.S., Wang X., Lu G., Picinich S.C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009, 9:429-439.
16. Johnson J.J., Bailey H.H., Mukhtar H. Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 2010, 17:3-13.
17. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66:1234-1240.
18. Brausi M., Rizzi F., Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008, 54:472-473.
19. Siddiqui I.A., Adhami V.M., Bharali D.J., et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009, 69:1712-1716.
20. Sanna V., Pintus G., Roggio A.M., et al. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J Med Chem 2011, 54:1321-1332.
21. Davis M.I., Bennett M.J., Thomas L.M., Bjorkman P.J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A 2005, 102:5981-5986.
22. Rocha S., Generalov R., Pereira Mdo C., Peres I., Juzenas P., Coelho M.A. Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention. Nanomedicine 2011, 6:79-87.
23. Farokhzad O.C., Cheng J., Teply B.A., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103:6315-6320.
24. Gu F., Langer R., Farokhzad O.C. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol 2009, 544:589-598.
25. Gu F., Zhang L., Teply B.A., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 2008, 105:2586-2591.
26. Alexis F., Pridgen E.M., Langer R., Farokhzad O.C. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 2010, 197:55-86.
27. Thangapazham R.L., Puri A., Tele S., Blumenthal R., Maheshwari R.K. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 2008, 32:1119-1123.
28. Sanna V., Roggio A.M., Posadino A.M., et al. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett 2011, 6:260.
29. Peng W., Anderson D.G., Bao Y., Padera R.F., Langer R., Sawicki J.A. Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors. Prostate 2007, 67:855-862.
30. Goldstein D., Gofrit O., Nyska A., Benita S. Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer. Cancer Res 2007, 67:269-275.
31. Krishnan S., Diagaradjane P., Cho S.H. Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int J Hyperthermia 2010, 26:775-789.
32. Walter J.G., Petersen S., Stahl F., Scheper T., Barcikowski S. Laser ablation-based one-step generation and bio-functionalization of gold nanoparticles conjugated with aptamers. J Nanobiotechnol 2010, 8:21.
33. BIND Biosciences initiates Phase 1 clinical study of BIND-014. Available from: http://www.bindbio.com/content/pages/news/news_detail.jsp/q/news-id/55.
34. Shi J., Xiao Z., Kamaly N., Farokhzad O.C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011, 44:1123-1134.
35. Thaxton C.S., Elghanian R., Thomas A.D., et al. Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A 2009, 106:18437-18442.
36. Viator J.A., Gupta S., Goldschmidt B.S., et al. Gold nanoparticle mediated detection of prostate cancer cells using photoacoustic flowmetry with optical reflectance. J Biomed Nanotechnol 2010, 6:187-191.
37. Johannsen M., Gneveckow U., Thiesen B., et al. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol 2007, 52:1653-1661.
38. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
39. Huo Q., Colon J., Cordero A., et al. A facile nanoparticle immunoassay for cancer biomarker discovery. J Nanobiotechnology 2011, 9:20.
40. Lee C.M., Jeong H.J., Cheong S.J., et al. Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm Res 2010, 27:712-721.
41. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010, 62:1052-1063.
42. Gindy M.E., Prud'homme R.K. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 2009, 6:865-878.
43. Wang A.Z., Bagalkot V., Vasilliou C.C., et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3:1311-1315.
44. Bagalkot V., Zhang L., Levy-Nissenbaum E., et al. Quantum dot - aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer. Nano Lett 2007, 7:3065-3070.
45. Kim D., Jeong Y.Y., Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 2010, 4:3689-3696.
46. Agemy L., Sugahara K.N., Kotamraju V.R., et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood 2010, 116:2847-2856.
47. Lukianova-Hleb E.Y., Oginsky A.O., Samaniego A.P., et al. Tunable plasmonic nanoprobes for theranostics of prostate cancer. Theranostics 2011, 1:3-17.
48. Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H. Nanomedicine - challenge and perspectives. Angew Chem Int Ed Engl 2009, 48:872-897.
49. Godin B., Tasciotti E., Liu X., Serda R.E., Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011, 44:979-989.
50. Zolnik B.S., González-Fernández A., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.